BioTroy Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$27.8M
- Investors
-
13
BioTroy Therapeutics General Information
Description
Developer of immuno-oncology therapeutics designed to discover novel therapeutic targets and develop cancer treatments. The company offers tumour immunology research platforms, antibody discovery technologies, biopharmaceutical development capabilities, and companion diagnostic reagents, enabling oncology researchers, pharmaceutical companies, and healthcare providers to advance targeted cancer therapies and precision medicine programs.
Contact Information
Website
www.biotroy.cnCorporate Office
- Room 203, Building 1
- Number 1227 Zhangheng Road, Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- Room 203, Building 1
- Number 1227 Zhangheng Road, Pudong New Area
- Shanghai, 201203
- China
BioTroy Therapeutics Timeline
BioTroy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series A) | 17-Jun-2025 | $27.8M | Completed | Generating Revenue | ||
| 4. Early Stage VC | 28-Mar-2025 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 31-Jan-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 19-Jan-2022 | $15.7M | $15.7M | Completed | Generating Revenue | |
| 1. Seed Round | 29-Sep-2021 | Completed | Startup |
BioTroy Therapeutics Patents
BioTroy Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026189535-A1 | Anti-cd3l1 antibody-drug conjugate and use thereof in preparation of anti-tumor drug | Pending | 14-Mar-2025 | ||
| WO-2026189535-A9 | Anti-cd3l1 antibody-drug conjugate and use thereof in preparation of anti-tumor drug | Pending | 14-Mar-2025 | ||
| WO-2026061529-A1 | Use of mageb16 modulator in preparation of product for treating autoimmune disease or resisting tumor | Pending | 23-Sep-2024 | ||
| JP-7938962-B2 | A method for suppressing tumor cell proliferation based on ccdc112 | Active | 08-Feb-2021 | ||
| AU-2022216578-A1 | Method for inhibiting tumour cell growth based on ccdc112 | Pending | 08-Feb-2021 | C07K16/28 |
BioTroy Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Shanghai Industrial Capital Management | Growth/Expansion | Minority | ||
| ZhongMei Capital | Venture Capital | Minority | ||
| Lapam Capital | Venture Capital | Minority | ||
| Pudong Capital | Venture Capital | Minority | ||
| Shanghai Science and Technology Innovation Center Equity Investment Fund Management | Fund of Funds | Minority |
BioTroy Therapeutics FAQs
-
When was BioTroy Therapeutics founded?
BioTroy Therapeutics was founded in 2020.
-
Where is BioTroy Therapeutics headquartered?
BioTroy Therapeutics is headquartered in Shanghai, China.
-
What industry is BioTroy Therapeutics in?
BioTroy Therapeutics’s primary industry is Biotechnology.
-
Is BioTroy Therapeutics a private or public company?
BioTroy Therapeutics is a Private company.
-
What is BioTroy Therapeutics’s current revenue?
The current revenue for BioTroy Therapeutics is .
-
How much funding has BioTroy Therapeutics raised over time?
BioTroy Therapeutics has raised $69.8M.
-
Who are BioTroy Therapeutics’s investors?
Shanghai Industrial Capital Management, ZhongMei Capital, Lapam Capital, Pudong Capital, and Shanghai Science and Technology Innovation Center Equity Investment Fund Management are 5 of 13 investors who have invested in BioTroy Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process